Evidence map›Paper›PMID 42698410›Full record

ArticleFrontiers in oncology2026

Case Report: Safety and efficacy of tarlatamab for SCLC in a liver transplant recipient.

Jonas Leonhardt, Johann Pratschke, Jürgen Behr, Jeremias Götschke, Philipp Jurmeister, Diego Kauffmann-Guerrero, Frederick Klauschen, Laura Lambrecht, Paula Mras, Christian Schneider and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jonas Leonhardt *Department of Medicine V, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany.
Johann Pratschke *Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Jürgen BehrDepartment of Medicine V, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany.
Jeremias GötschkeDepartment of Medicine V, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany.
Philipp JurmeisterInstitute of Pathology, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany.
Diego Kauffmann-GuerreroDepartment of Medicine V, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany.
Frederick KlauschenBavarian Cancer Research Center (BZKF), Munich, Germany.
Laura LambrechtDepartment of Medicine V, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany.
Paula MrasDepartment of Medicine V, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany.
Christian SchneiderDepartment of Thoracic Surgery, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany.
Blerina ResuliDepartment of Medicine V, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany.
Amanda TufmanDepartment of Medicine V, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tarlatamab is a bispecific T-cell engager used for the treatment of small cell lung cancer (SCLC). Patients with a history of solid organ transplantation carry an elevated risk of malignancy yet are excluded from most clinical trials. We report the first case of Tarlatamab use in a liver transplant recipient with SCLC, resulting in marked tumor response and a favorable safety profile without evidence of graft rejection.

Indexed as

delta-like ligand 3small cell lung cancersolid organ transplant recipienttargeted therapytarlatamab

Identifiers

PMID42698410
PMCPMC13541477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.